

Lutetium-177 Chloride

Precision radiotherapy, global reliability



Lu-177: Precision and reliability in targeted radiotherapy

Lutetium-177 (Lu-177) offers a powerful radionuclide solution for treating prostate cancer and neuroendocrine tumors.

As a beta-emitting isotope, Lu-177 delivers localized radiation to cancer cells while minimizing damage to surrounding healthy tissue, making it a key component in cancer treatments.

Reliable global supply chain

At Isotopia, we produce high-purity Lu-177, non-carrier-added (n.c.a), and carrier-added (c.a) in GMP certified facilities, ensuring these products meet regulatory approved specifications for safety and efficacy.

Our extensive supply of critical starting materials, surplus irradiation capacity located around the globe, and our robust, commercial-scale manufacturing processes provide a stable, continuous supply of isotopes to our pharmaceutical customers, enabling healthcare providers worldwide to confidently deliver cutting-edge, patient-centered therapies.

Gold standard service – Complete and attentive support, direct communication with our professional team of experts.



Supplying all phases — from preclinical to commercial

Supply to all phases of pharmaceutical development from preclinical to commercial applications

Supply chain robustness built into all aspects of isotope manufacturing:

Substantial precursor supply, multi-site irradiation capacity, global isotope production facility footprint.

Shorter time from irradiation to patient

- · Save pre-calibration costs and reach more patients
- De-risk the logistics
- · Backup and surplus between all manufacturing sites

High Quality

- Full compliance with cGMP regulations
- US FDA DMF
- Health Canada MF*
- EU Marketing Authorization available*
- Certified Type A package for safe global shipping
- Authorized Manufacturer, Importer, Distributor, Exporter (MIDE)

^{*}Applicable for n.c.a only



Tell us what you need



About Isotopia

Since 2006, Isotopia Molecular Imaging has been at the forefront of innovation in nuclear medicine, transforming patient care through cutting-edge solutions.

Driven by our scientific expertise and commitment to solving unmet medical needs, we develop, produce, and supply advanced diagnostic and therapeutic radioactive isotopes and cold kits worldwide.

With strategically located production facilities in Israel, the USA, and Austria, we ensure a reliable supply chain that minimizes patient risk and guarantees uninterrupted access to life-extending treatments.

Our unwavering focus on consistency and sustainability empowers healthcare professionals to deliver uninterrupted, high-quality care where it's needed most.

Lutetium (Lu-177) Specifications

| Chemical Form | LuCl ₃ in HCl 0.04N | |
|---------------|--|--|
| Packaging | 10 mL molded vial closed with fluorotec septum and open top crimp seal 5 mL V-shaped vial closed with fluorotec septum and open top crimp seal | |

| | Specification | | |
|---|--|--|--|
| Test | n.c.a | c.a | |
| Appearance | Clear, colorless solution | Clear, colorless solution | |
| рН | 1.0 – 2.0 | 1.0 – 2.0 | |
| Identification A (Gamma spectrometry) | Gamma photons with 208 KeV and 113 KeV present | Gamma photons with 208 KeV and 113 KeV present | |
| Identification B (pH) | 1.0 – 2.0 | 1.0 - 2.0 | |
| Identification C (iTLC) | The retardation factor of the principal peak in the chromatogram obtained in the test for radiochemical purity is 0.4 to 0.7 | The retardation factor of the principal peak in the chromatogram obtained in the test for radiochemical purity is 0.4 to 0.7 | |
| Specific Activity (by ICP-OES at end of production) | >3000 GBq/mg (>81 Ci/mg) | >740 GBq/mg (>20 Ci/mg) | |
| Chemical Purity (by ICP- OES at end of shelf life) | Cu ≤ 1.0 μg/GBq Fe ≤ 0.5 μg/GBq Pb ≤ 0.5 μg/GBq Zn ≤ 1.0 μg/GBq Yb ≤ 1.0 μg/GBq | Cu ≤ 1.0 μg/GBq Fe ≤ 0.5 μg/GBq Pb ≤ 0.5 μg/GBq Zn ≤ 1.0 μg/GBq | |
| Radionuclidic Purity (Gamma spectrometry at end o shelf life) | ¹⁷⁵ Yb ≤ 0.1% | ^{177m} Lu ≤ 0.07% | |
| | The total radioactivity due to other radionuclides impurities ≤ 0.01% | The total radioactivity due to other radionuclides impurities ≤ 0.01% | |
| Radiochemical Purity (by iTLC) | [¹ ⁷⁷ Lu]lutetium(III) ion ≥ 99% | [¹⁷⁷ Lu]lutetium(III) ion ≥ 99% | |
| Bacterial endotoxins | < 35 EU/mL | < 35 EU/mL | |
| Sterility | Sterile (by autoclaving) | Sterile (by autoclaving) | |

03 04



Lu-177 Lu





Isotopia Molecular Imaging LTD

39 Alexander Yanai St Segula Industrial Park Petach Tikva 4927735 | Tel +972 3 913 0314 Info@isotopia-global.com | isotopia-global.com Isotopia USA Inc. 17075 Oak Ridge Rd Westfield, IN 46074, USA InfoUSA@isotopia-global.com|isotopia-global.com